Bayer Donates 300,000 Tablets of Chloroquine Phosphate to Support China's Fight Against COVID-19

February 20, 2020 News /BioValleyBIOON/ -- Bayer Group recently announced that its subsidiary in Pakistan, at the request of the Guangdong Provincial Government, urgently allocated 300,000 tablets of Resochin® (chloroquine phosphate tablets) this month and provided them free of charge. The first batch was approved on an expedited basis within 24 hours, and international aid efforts—including production, stock preparation, and transportation—were completed in the shortest possible time to support pandemic prevention and control material reserves and for supplyClinical TrialsUse.

Resochin® (chloroquine phosphate tablets) is an original drug first synthesized by Bayer AG in Germany, and has been used clinically as an antimalarial agent for over 70 years. Previous studies have shown that it not only has antimalarial effects, but alsoPossesses broad-spectrum antiviral activity, andExcellent immunomodulatory effects。

According to reports, at the press conference held by the State Council’s Joint Prevention and Control Mechanism on February 17, a representative from the Biotechnology Center of the Ministry of Science and Technology stated that, based on the research findings conducted by clinical institutions in the early stage,It is clear that chloroquine phosphate has a certain therapeutic effect in the treatment of COVID-19.Chloroquine PhosphateIncluded in the New Edition of Clinical Practice Guidelines, expanding clinical indications. Click for details：Interpretation of the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6)。

As a life sciences company, Bayer remains committed to its mission of “Science For A Better Life,” upholding the responsibilities of a leading enterprise in the pharmaceutical and healthcare industry by providing its proprietary innovative medicines and delivering international aid at the earliest opportunity. Following its initial donation of urgently needed medical supplies and funds totaling RMB 11 million at the outset of the pandemic, Bayer employees across China and the Asia-Pacific region have joined hands, actively engaging in cross-regional and cross-functional teamwork to once again go all out in taking concrete actions to support and contribute to the fight against the epidemic.

Jiang Wei, Global Executive Vice President of Bayer AG’s Pharmaceuticals Division and President of China and Asia-Pacific, as well as President of Greater China for Bayer AG, stated: “We are deeply committed to the health of patients and healthcare professionals in China. By leveraging our expertise in the pharmaceutical and healthcare sectors, we remain steadfast in our commitment to patients and healthcare workers, and fully support the national efforts in epidemic prevention and control. We are pleased that Bayer’s original research-based medicines can contribute to the fight against the epidemic. The outbreak has touched the hearts of Bayer employees worldwide. We will always stand together with everyone, offering mutual support and joining forces to combat the epidemic.” (Bioon.com)

Original Source: Bayer AG